Background: Osteoporosis (OP) is a metabolic bone illness that may complicate celiac disease (CD). It can lead to devastating consequences because of low bone mass and fragility fractures. Purpose: To study the OP prevalence in a group of Brazilian patients with CD and the value of a gluten free diet (GFD). Methods: Retrospective study of celiac female patients from a single University Center followed with bone densitometries. Results from densitometry made at first visit were compared with a second study after a median time of 5 years. During this period, patients were submitted to a GFD according to orientations from special program training. Calcium and vitamin D were prescribed to those patients who did not reach the minimal daily requirement through diet. Results: Forty-one celiac female patients, mean age 46.1 ± 14.8 years, were included. The prevalence of osteopenia at first visit was 56.1% and that of osteoporosis 29.2%. Osteoporosis was associated with longer disease duration (p = 0.01). The second densitometry was performed in a median time of 5 years (range 1 to 13 years) and disclosed 58.9% osteopenia and 28.2% osteoporosis. The GFD improved bone mass, mainly at (of) spine (comparison of T score with p = 0.03 and of bone mass in g/cm² with p = 0.02), but it was not sufficient to reduce the number of osteopenic (p = 0.9) and osteoporotic patients (p = 0.4). During the follow up period 25% of osteoporotic patients developed low impact fractures. Conclusion: Bone health is notably impaired at baseline in CD patients, especially in those with a diagnostic delay. A GFD modestly improved bone mass density with low impact fractures occurring in one third of patients during the follow up period.

OBJETIVO: Determinar as concentrações de hormônio estimulante da tireóide (TSH) e a presença de anticorpos antitireoperoxidase (anti-TPO) em pacientes com síndrome de Down (SD) atendidos no ambulatório do Hospital de Clínicas da Universidade Federal do Paraná. MÉTODOS: Foram incluídos no estudo 72 pacientes com SD, não aparentados e selecionados consecutivamente, com média de idade de 6,15 anos. Oitenta crianças sadias, pareadas com os pacientes, foram utilizadas como controles. Em todas as amostras foram determinadas as concentrações séricas de TSH e de anti-TPO, através do método de dosagem imunométrica. RESULTADOS: Trinta pacientes com SD (42,9%) apresentaram alterações nas concentrações de TSH, sendo que 4,3% tinham valores menores que 0,5µUI/ml e 38,6%, valores superiores a 5µUI/ml (5,1 a 22) (média de 5,56 ± 4,18µUI/ml). Nos controles, a concentração média de TSH foi 2,76µUI/ml (± 1,14), evidenciando-se um aumento significativo nos níveis de TSH nos pacientes com SD (p < 0,001). De forma similar, caracterizou-se uma diferença significativa na positividade para o anti-TPO nos pacientes (15,4%) em relação aos controles (0%; p < 0,001). Observou-se ainda aumento significativo nas concentrações de TSH nos pacientes com idade superior a 9 anos (média de 6,86 ± 4,6µUI/ml) quando comparados aos menores de 9 anos (média de 5,24 ± 3,81µUI/ml; p = 0,006), bem como na positividade do anti-TPO (6/20 vs. 5/52; p = 0,041). CONCLUSÕES: Os resultados demonstraram alta prevalência de alterações das dosagens de TSH e de doença tireoidiana nos pacientes com SD, principalmente naqueles com idade superior a 9 anos. Os dados indicam que a avaliação da função tireoidiana nos pacientes com SD deve receber atenção especial dos profissionais de saúde que atendem esses pacientes.

OBJECTIVE: To evaluate the thyroid stimulating hormone (TSH) levels and the presence of antithyroperoxidase antibody (anti-TPO) in Down’s syndrome (DS) patients from Hospital de Clínicas of Universidade Federal do Paraná (HC/UFPR). METHODS: Seventy-two DS patients, non-related and consecutively selected (mean age 6.15) were included in the study. Eighty matched healthy children were used as controls. The TSH measurement and the anti-TPO were determined by immunometric assay in all samples. RESULTS: Thirty patients with DS (42.9%) presented abnormal levels of TSH; 4.3% showed values below 0.5µIU/ml and 38.6% presented values higher than 5µIU/ml (range 5.1-22; mean 5.56 ± 4.18µIU/ml). The mean concentration of TSH in the controls was 2.76 ± 1.14µIU/ml, indicating a significant increase in TSH levels in the DS patients (p < 0.001). Similarly, a significant difference was observed in the anti-TPO positivity in the patients’ group (15.4%) when compared with the controls (0%; p < 0.001). In addition, the TSH levels of patients older than 9 years presented a significant increase (mean of 6.86 ± 4.6µIU/ml) when compared with the levels observed in patients younger than 9 years (mean of 5.24 ± 3.81µIU/ml; p = 0.006). The same pattern was observed in the positivity of anti-TPO (6/20 vs. 5/52; p = 0.041). CONCLUSIONS: The results demonstrated high prevalence of elevated TSH and anti-TPO in the patients from the DS ambulatory of HC/UFPR, with increased frequency in those older than 9 years. The data indicate that the evaluation of thyroid function in DS patients must receive special attention from health professionals who take care of these patients.